Analysis Tools|
Allele Symbol Allele Name Allele ID |
Ikbkgtm1.1Chtr targeted mutation 1.1, Christian Trautwein MGI:4355682 |
||||||||||||||||||||||||||||
| Summary |
6 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• mice exhibit biliary lesions
|
|
|
• mice exhibit necrotic liver injury (three types of injury are seen) which is maximal at 6-8 weeks of age
• 34% of mice exhibit few white liver lesions identified as necrotic areas (type I liver)
• 40% of mice exhibit multilocular, visible white liver lesions with features of parenchymal necroses or bile infarcts and increased liver weight (type II liver)
• 26% of mice exhibit yellow livers, increased liver size, multilocular yellow lesions resulting in massive necrotic destruction of the liver associated with multiple bile infarcts, and exhibit dwarfism (type III liver)
• increase in cell proliferation (not hepatocytes) in the liver
|
|
|
• hepatomegaly is seen in mice with type II and III livers
|
|
|
• mice exhibit necrotic liver injury which is maximal at 6-8 weeks of age
• ageing mice recover from necrotic liver injury and are protected from steatosis but develop liver fibrosis
|
|
|
• ageing mice recover from necrotic liver injury but develop liver fibrosis
|
|
|
• dwarfism is seen in mice with type III livers
|
|
|
• hepatomegaly is seen in mice with type II and III livers
|
|
|
• increase in bilirubin levels in mice with type III livers
|
|
|
• serum transaminase levels are increased in mice with type II and III livers
|
|
|
• alkaline phosphatase levels are elevated in correlation to severity of liver injury
|
|
|
• increase in bile acid levels in mice with type III livers
|
|
N |
• mice do not develop hepatocellular carcinoma are remain tumor free up to 60 weeks of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 N |
• mice exhibit normal survival throughout 50 weeks
|
|
N |
• bile ducts are normal at 6 weeks
|
|
N |
• mice exhibit normal bilirubin serum levels
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Inflammation and steatohepatitis in 12 week old Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0 and Ikbkgtm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0 mice
|
|
• all mice treated with concanavalin A die unlike similarly treated mice not carrying the cre transgene
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• before and after treatment with concanavalin A compared with Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 lowers TNF levels
|
|
|
• before and after treatment with concanavalin A compared with Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 or ASIALO antibodies lowers IFN-gamma levels induced by concanavalin A
• mice treated with concanavalin A, NK1.1 antibodies, and wild-type mononuclear cells exhibit elevated serum IFN-gamma levels compared to mice treated with concanavalin A and NK1.1 antibodies
• however, mice treated with concanavalin A, NK1.1 antibodies and Tnfsf10tm1Mjs mononuclear or NK/NKT cells exhibit reduced IFN-gamma levels
|
|
|
• at 12 weeks, mice exhibit liver inflammation unlike in Ikbkgtm1.1Chtr mice
• mice treated with concanavalin A develop more severe hepatitis than similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases liver damage in untreated and concanavalin A treated mice
|
|
|
• mice treated with concanavalin A exhibit increased apoptosis compared to similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 or ASIALO antibodies reduces apoptosis induced by concanavalin A
|
|
|
• at 12 weeks, mice exhibit liver inflammation unlike in Ikbkgtm1.1Chtr mice
• mice treated with concanavalin A develop more severe hepatitis than similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases liver damage in untreated and concanavalin A treated mice
|
|
|
• at 12 weeks, livers are dysplastic and display anisokaryosis unlike in wild-type mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases liver damage in untreated mice and mice treated with concanavalin A
• however, depletion of NK/NKT cells with ASIALO antibodies decreases liver damage induced by concanavalin A
• mice treated with concanavalin A, NK1.1 antibodies, and wild-type mononuclear cells exhibit increased liver damage compared to mice treated with concanavalin A and NK1.1 antibodies
• however, mice treated with concanavalin A, NK1.1 antibodies and Tnfsf10tm1Mjs mononuclear or NK/NKT cells exhibit reduced liver damage
|
|
|
• at 1 year
|
|
|
• hepatic necrosis is observed in mice treatment with concanavalin A unlike in similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 improves necrosis induced by concanavalin A
|
|
|
• at 12 weeks
|
|
|
• at 1 year
|
|
|
• before and after treatment with concanavalin A compared with Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 lowers TNF levels
|
|
|
• at 12 weeks, mice exhibit elevated serum alanine transaminase (ALT) levels compared to in Ikbkgtm1.1Chtr mice
• mice treated with concanavalin A exhibit increased serum ALT levels compared with similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases ALT levels in untreated mice and mice treated with concanavalin A
• however, depletion of NK/NKT cells with ASIALO antibodies decreases ALT levels mice treated with concanavalin A
• mice treated with concanavalin A, NK1.1 antibodies, and wild-type mononuclear cells exhibit elevated ALT levels compared to mice treated with concanavalin A and NK1.1 antibodies
• however, mice treated with concanavalin A, NK1.1 antibodies and Tnfsf10tm1Mjs mononuclear or NK/NKT cells exhibit reduced ALT levels
|
|
|
• all mice treated with concanavalin A die unlike similarly treated mice not carrying the cre transgene
|
|
|
• mice treated with concanavalin A develop more severe hepatitis, high ALT, necrosis, and apoptosis than similarly treated Ikbkgtm1.1Chtr mice
• all mice treated with concanavalin A exhibit increased interferon-gamma and TNF levels compared to in similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with ASIALO antibodies decreases liver damage, liver apoptosis, ALT levels, and IFN-gamma levels induced by concanavalin A
• mice treated with concanavalin A, NK1.1 antibodies, and wild-type mononuclear cells exhibit elevated ALT and IFN-gamma levels and liver damage compared to mice treated with concanavalin A and NK1.1 antibodies
• however, mice treated with concanavalin A, NK1.1 antibodies and Tnfsf10tm1Mjs mononuclear or NK/NKT cells exhibit reduced ALT and IFN-gamma levels and liver damage
|
|
|
• at 1 year
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• mice treated with concanavalin A exhibit increased apoptosis compared to similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 or ASIALO antibodies reduces apoptosis induced by concanavalin A
|
|
|
• at 1 year
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Ikbkgtm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0 mice are protected from anti-Fas mAb stimulated development of hepatitis
|
|
• 90% of mice treated with anti-Fas mAB (Jo2) survive where as all similarly treated Ikbkgtm1.1Chtr mice die
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• at 12 weeks, mice exhibit liver inflammation unlike in Ikbkgtm1.1Chtr mice
• mice treated with TRAIL (Tnfsf10) exhibit by profuse PMN infiltration in the liver compared to in similarly treated Ikbkgtm1.1Chtr mice
|
|
|
• mice treated with TRAIL (Tnfsf10) exhibit increased apoptosis compared to similarly treated Ikbkgtm1.1Chtr mice
• however, treatment with JNK inhibitor AS600125 prevents TRAIL (Tnfsf10) induced liver apoptosis
|
|
|
• at 12 weeks, mice exhibit liver inflammation unlike in Ikbkgtm1.1Chtr mice
• mice treated with TRAIL (Tnfsf10) exhibit by profuse PMN infiltration in the liver compared to in similarly treated Ikbkgtm1.1Chtr mice
|
|
|
• at 12 weeks, livers are dysplastic and display anisokaryosis unlike in wild-type mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases liver damage
|
|
|
• at 1 year
|
|
|
• at 12 weeks, mice exhibit elevated serum alanine transaminase (ALT) levels compared to in Ikbkgtm1.1Chtr mice
• mice treated with TRAIL (Tnfsf10) exhibit increased serum ALT levels compared with similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 antibodies decreases ALT levels
|
|
|
• hepatic necrosis is observed in mice treatment with TRAIL (Tnfsf10) unlike in similarly treated Ikbkgtm1.1Chtr mice
• however, depletion of NK/NKT cells with NK1.1 improves necrosis induced by TRAIL (Tnfsf10)
|
|
|
• 90% of mice treated with anti-Fas mAB (Jo2) survive where as all similarly treated Ikbkgtm1.1Chtr mice die
|
|
|
• anti-Fas mAB (Jo2)-treated mice do not exhibit hepatic blood accumulation, further increased liver weight, further increased alanine transaminase serum levels, hepatic necrosis, or hepatic apoptosis as observed in similarly treated Ikbkgtm1.1Chtr mice
|
|
|
• at 1 year
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• NK1.1+ cells have a higher level of annexin V than in NK1.1+ cells from Ikbkgtm1.1Chtr mice
|
|
|
• mice treated with TRAIL (Tnfsf10) exhibit increased apoptosis compared to similarly treated Ikbkgtm1.1Chtr mice
• however, treatment with JNK inhibitor AS600125 prevents TRAIL (Tnfsf10) induced liver apoptosis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
N |
• mice exhibit normal bile ducts and no liver necrosis
|
|
|
• at 14 weeks, livers exhibit an increase in hydroproline content compared with wild-type liver
|
|
|
• at 50 weeks but not at 21 to 26 weeks
|
|
|
• at 6 weeks, mice exhibit periportal liver fibrosis unlike wild-type mice
• at 20 to 29 weeks, mice exhibit severe diffuse fibrosis unlike wild-type mice
|
|
N |
• mice exhibit normal bilirubin serum levels
|
|
|
• milder than in Map3k7tm1Aki/ Map3k7tm1Aki Tg(Alb1-cre)7Gsc mice
|
|
|
• milder than in Map3k7tm1Aki/ Map3k7tm1Aki Tg(Alb1-cre)7Gsc mice
|
|
|
• at 6 weeks, circulating glutamate dehydrogenase is increased compared to in wild-type mice
|
|
|
• at 50 weeks but not at 21 to 26 weeks
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
